Germany's Fresenius Medical Q2 revenue beats; 2026 outlook reaffirmed
Germany's Fresenius Medical Q2 revenue beats; 2026 outlook reaffirmed
Overview
Germany dialysis provider's Q2 revenue rose 1% yr/yr, beating analyst expectations
Q2 operating income grew 10% yr/yr; net income declined 3%
Company reaffirmed 2026 outlook
Outlook
Fresenius Medical reaffirms 2026 revenue growth to be broadly flat versus prior year
Company expects 2026 operating income to be in a positive to negative mid-single digit percent range
2026 outlook is at constant currency and excludes special items in operating income
Result Drivers
RATE AND REIMBURSEMENT EFFECTS - Co said positive rate effects and favorable TDAPA reimbursement regulations supported operating income growth
COST SAVINGS - FME25+ transformation program delivered EUR 67 mln in additional sustainable savings in Q2
5008X CARESYSTEM ROLLOUT - Increased sales and rollout of 5008X CAREsystem in U.S. clinics contributed to segment growth
Company press release: ID:nPn2s1t75a
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Revenue | Beat | EUR 4.86 bln | EUR 4.79 bln (7 Analysts) |
Q2 Net Income |
| EUR 218 mln |
|
Q2 Basic EPS |
| EUR 0.81 |
|
Q2 EBIT |
| EUR 466 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 7 "strong buy" or "buy", 8 "hold" and 8 "sell" or "strong sell"
The average consensus recommendation for the healthcare facilities & services peer group is "buy."
Wall Street's median 12-month price target for Fresenius Medical Care AG is €41.50, about 7.5% below its August 3 closing price of €44.86
The stock recently traded at 11 times the next 12-month earnings vs. a P/E of 9 three months ago
Reuters Recommended Reads
Aug 3 - Fresenius Medical Care beats quarterly profit estimates, sticks to 2026 outlook
Aug 3 - BioNTech says Sobi's Oelkers will replace Sahin as CEO
Aug 3 - Supernus Q2 revenue rises on prescription volume; to merge with Indivior Pharma
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
Recent news on Fresenius Medical Care AG
See all newsFMC seen down as Fresenius cuts stake to 20%
Germany's Fresenius cuts FMC stake to 20%
Brief: Fresenius Investment In Fresenius Medical Care Reduced From Approximately 25% To Approximately 20% Of Issued Share Capital
Brief: Fresenius Medical Care AG ABB Orders Below Eur 39.00 Per Share, Says Book Runner
Brief: Bookrunner Says Fresenius Medical ABB C. 13.4 Mln Shares, Books Are Closed